



Kilitch Drugs (India) Ltd.

4<sup>th</sup> February, 2026

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Intimation of the Board Meeting**

Dear Sir,

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held on Wednesday, 11<sup>th</sup> February, 2026 inter-alia to consider and approve the following;

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 31<sup>st</sup> December, 2025;
2. Increase in Authorised Capital of the Company, subject to member approval;
3. To recommend and approve issue of Bonus Shares to the existing Equity Shareholders of the Company, subject to members approval;
4. To finalise the date, venue and time for convening the Extra-ordinary General Meeting of the Member of the Company;
5. To finalise the Record Date;
6. To consider appointment of scrutinizer to oversee the e-voting process of the Company at the Extra-Ordinary General Meeting;
7. Any other matter with the permission of the Chair.

Further in accordance with the Code of Conduct for prevention of Insider Trading framed by the Company pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company has been closed for all Directors/Officers/Connected/Designated Persons of the Company and their immediate relatives from 1<sup>st</sup> January, 2026 and the same will remain closed till 48 hours after the announcement is made available to public. Accordingly, all Directors/Officers/Connected Persons/Designated Persons of the Company and their immediate relatives have been informed not to trade in the securities of the Company during the aforesaid period of closure of Trading Window.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147876**

